35450-81-8

Upstream product

• 134029-62-2 (E)-3,4,4',5-tetramethoxystilbene 
• 75921-68-5 1,2,3-trimethoxy-5-(methoxymethyl)benzene 
• 824-94-2 p-methoxybenzyl chloride 
• 14425-64-0 4-methoxyphenethyl bromide 
• 2675-79-8 1-bromo-3,4,5-trimethoxybenzene 
• 35450-75-0 3,4'-Dihydroxy-4,5-dimethoxybibenzyl 
• 74-88-4 methyl iodide 
• 39499-96-2 4,4′-dihydroxy-3,5-dimethoxybibenzyl 
• 61240-20-8 triphenyl-(3,4,5-trimethoxybenzyl)phosphonium bromide 
• 141172-33-0 3,4,5-trimethoxy-α-[(4-methoxyphenyl)methylene]-(E)-benzeneacetic acid 
• 951-82-6 3,4,5-trimethoxyphenyl acetic acid 

Relevant academic research and scientific papers

Ligand-Controlled Nickel-Catalyzed Reductive Relay Cross-Coupling of Alkyl Bromides and Aryl Bromides

1,1-Diarylalkanes are important structural frameworks which are widespread in biologically active molecules. Herein, we report a reductive relay cross-coupling of alkyl bromides with aryl bromides by nickel catalysis with a simple nitrogen-containing ligand. This method selectively affords 1,1-diarylalkane derivatives with good to excellent yields and regioselectivity.

Ion pairing effects on the regioselectivity of arylic versus benzylic C-O bond reductive cleavage: synthetic applications

The regioselectivity of the reductive cleavage of 3,4,5-trimethoxybenzyl methyl ether strongly depends on the alkali metal employed as a reducing agent and solvent effects. Reactions run using Na as a reducing agent led to aromatic C(4)-O bond cleavage, whilst reductions run in the presence of Na/15-crown-5, or using Li as a reducing agent, led to highly regioselective benzylic C-O bond cleavage. This regioselectivity turnaround is discussed in terms of major solvent effects affecting the fragmentation paths of a common reaction intermediate. Synthetic applications of these findings led to the synthesis of biologically active compounds, like 2,5-dialkyl-substituted resorcinols, or 1-(3,4,5-trimethoxyphenyl)-2-arylethanes structurally related to combretastatin.

Stilbene derivatives as anticancer agents

The present invention relates to stilbene derivatives which possess utility as anti-cancer agents. The compounds can be used to treat cancers which are susceptible to treatment therewith, and can be utilized in a method of treating such cancers. Pharmaceu

Synthesis and Evaluation of Stilbene and Dihydrostilbene Derivatives as Potential Anticancer Agents That Inhibit Tubulin Polymerization

An array of cis-, trans-, and dihydrostilbenes and some N-arylbenzylamines were synthesized and evaluated for their cytotoxicity in the five cancer cell cultures A-549 lung carcinoma, MCF-7 breast carcinoma, HT-29 colon adenocarcinoma, SKMEL-5 melanoma, a